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ABSTRACT 
Guo Hu: Effects of liver-specific ACSL4 (long-chain acyl-Coenzyme A synthetase 4) 
deletion in liver lipid metabolism 
(Under the direction of Dr. Rosalind Coleman) 
 
Long-chain Acyl-CoA synthetases (ACSLs) are a family of enzymes that catalyze the 
thioesterification of free fatty acid to fatty acyl-CoA.  One member of this family, ACSL4 
has been found to be overexpressed 3-fold in patients with non-alcoholic fatty liver disease 
(NAFLD) though the role of ACSL4 in the pathogenesis of NAFLD is unknown.  We 
hypothesized that the absence of ACSL4 would prevent NAFLD development.  In order to 
test our hypothesis we developed a murine liver-specific Acsl4 knockout, fed them a high fat 
diet (HFD), and determined if they were protected from the development of fatty liver.  
Despite 20 weeks of a 45% HFD, no difference was observed in weight gain, insulin 
sensitivity, ACSL activity, liver triacylglycerol content, liver histology, or serum lipid 
metabolites between control and Acsl4 liver specific knockout animals.  These results 
indicated that Acsl4 liver-specific KO mice were not protected from developing a fatty liver. 
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Chapter I. Introduction 
 
1.1 Hepatic lipid metabolism 
The liver is one of the most metabolically active organs in the body and acts as the 
core lipid metabolic factory via fatty acid (FA) synthesis, complex lipid formation, very low-
density lipoprotein (VLDL) production and secretion, and fatty acid oxidation.  Each of these 
metabolic pathways involves numerous enzymes that interact with one another and are 
regulated through different genetic, hormonal, and nutritional conditions.  Acyl-CoA 
synthetase 4 (ACSL4) is – one of five ACSL isoforms – that catalyzes the initial step of free 
fatty acid activation.  Each isoform appears to have slightly different functions and it has not 
been established as to how and where those activated FAs might be used.  My goal was to 
investigate the function of ACSL4 in liver and determine its role in hepatic lipid metabolism. 
Lipid metabolism first begins with the digestion and absorption of fat from the 
diet.  Triglyceride digestion is initiated by lingual lipases which are secreted by the tongue 
and is further processed in the stomach [1].  The stomach is the primary site for 
emulsification of fat-soluble vitamins and dietary fat [1].  The emulsification process 
continues as the micelle moves towards the duodenum.  The pancreas secretes multiple 
enzymes, such as lipases, which hydrolyze dietary complex lipids with the help of bile and 
bile salts in the intestine.  FFA and 2-monoacylglycerol, which are disassembled from dietary 
triacylglycerol (TAG), are taken up by intestinal cells through protein-mediated, as well as 
protein- independent, processes [1].  Cholesterol esters (CE), phospholipids (PL), and
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re-synthesized TAG are exported through chylomicrons from intestinal cells into the 
circulation.  Lipoprotein lipase (LPL) hydrolyzes the TAG from chylomicrons for the use of 
peripheral tissues.  The remnant chylomicrons, along with VLDL remnants, are taken up by 
liver through LDL-receptors.  Within hepatocytes, lipid components, released from remnants, 
enter different metabolic pathways. Long-chain fatty acids are covalently bound and 
activated by ACSL and are partitioned into different metabolic pathways [2].   
Activated FAs that enter synthetic pathways can be stored in cytoplasmic lipid 
droplets (CLD) or incorporated into complex lipids.  The lipid formation pathway depends on 
whole body energy status and nutrient requirements.  Synthetic lipid mechanisms in liver 
include de novo lipogenesis, TAG, and phospholipid synthesis.  Acetyl-CoA carboxylase 
(ACC) catalyzes the conversion of acetyl-CoA to malonyl-CoA and is one of the rate-
limiting enzymes of de novo lipogenesis.  ACC activity is inhibited under energy-insufficient 
state.  Elongation of malonyl-CoA is catalyzed by fatty acid synthetase (FAS), which is 
expressed in both liver and adipose tissues, by adding acetyl-CoA in each round until the 
formation of palmitic acid.   The rate of de novo lipogenesis is highly regulated by hormones 
such as insulin and glucagon.  Insulin and glucagon are raised during fed and fasting states, 
respectively.  Furthermore, carbohydrate and specific fatty acid content such as n-3 
polyunsaturated fatty acid in different diets can alter the expression of lipogenic genes by 
activating transcription factors such as SREBP-1c, ChREBP, and PPAR-γ. 
TAG synthesis is initiated by FA activation catalyzed by ACSLs.  The following 
esterification steps are catalyzed by glycerophosphate acyltransferase (GPAT), 
lysophosphatidate acyltransferase and diacylglycerol acyltransferase (DGAT) which lead to 
the formation of lysophosphatidic acid (lyso-PA), diacylglycerol (DAG) and triacylglycerol 
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(TAG), respectively.  Phospholipid formation is processed by using intermediates from TAG 
synthesis pathway.  Phosphatidic acid (PA) derived from lyso-PA can be used as a backbone 
for phospholipid formation through two different mechanisms.  One pathway involves 
hydrolyzing the phosphate group from PA to form DAG, with DAG serving as a precursor 
for phosphatidylethanolamine (PE) and phosphatidylcholine (PC).  The other pathway 
accounts for the major phosphatidylinositol (PI) and phosphatidylglycerol (PG) production 
by catalyzing CDP-DAG formation from PA.  The fate of newly formed TAG and 
phospholipids in liver is controlled by whole body energy states, either to be accumulated 
into CLD or output by VLDL.   
Unlike adipose tissue, the major site for lipid storage, the liver serves as a distribution 
center for the exports of TAG, phospholipids, and CE by secreting these lipids into VLDL 
particles for delivery into the circulation for utilization in the peripheral tissues.  Hepatic 
levels of lipid and ApoB100 are the two main components which directly affect VLDL 
assembly.  Increased plasma non-esterified fatty acid (NEFA) induces VLDL production and 
hepatic esterification [3] which are exacerbated in an insulin-resistant state [4, 5].  Insulin 
decreases VLDL production by increasing ApoB100 protein degradation [6] and inhibiting 
microsomal triglyceride transfer protein (MTP) expression, a protein is required for 
lipoprotein assembly [7].  
The degradative pathway of activated fatty acids metabolism is β-oxidation. This 
pathway takes place in the mitochondria, resulting in formation of acetyl-CoA from acyl-
CoA.  These acetyl-CoAs can be used as energy production through tricarboxylic acid cycle 
(TCA) and electron transport chain.  Increased NADH and FADH, generated by the oxidation 
pathway and TCA cycle, donate electrons to the electron transport chain to drive ATP 
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synthesis for energy production.  The energy that is yielded from fatty acid oxidation is 
approximately 9 Kcal of energy per gram of fatty acid – more than twice the amount of what 
is produced from a gram of carbohydrates during glycolysis of glucose.  Under prolonged 
fasting or aerobic exercise, both of which require an increased energy supply, the main 
energy utilization shifts from glucose to FA.  
 
1.2 Role of ACS isoforms in lipid metabolism 
Long-chaine Acyl-Coenzyme A (acyl-CoA) synthetases (ACSLs) are a group of 
enzymes that play an essential role in lipid metabolism including de novo lipid synthesis, 
fatty acid degradation, and membrane remodeling.  Though all ACSL isoforms share the 
same capacity for thioesterification of free fatty acid to fatty acyl-CoA, the substrate 
specificity, subcellular location, and potential impact on downstream metabolic pathways 
differ amongst each of the ACSLs isoforms.   Although structurally similar to one another, 
the five ACSL members can be grouped based upon their difference of sequence homology 
and gene structure into two sub-groups: ACSL1/ACSL5/ACSL6 and ACSL3/ACSL4 [8].  
Most of the ACSL isoforms are membrane-associated, but ACSL4 variant 1 is found in the 
cytoplasm [9].  Though enzyme activity can be measured in multiple ways, accurate 
assessment of the activity of each isoform is still a major challenge because inhibitors of 
ACSL are the non-specificity.  For example, in the mitochondrial membrane, triacsin C can 
selectively inhibit the activity of ACSL1, ACSL3, and ACSL4 without affecting ACSL5 or 6 
[10, 11].  The activity of ACSL4 is selectively and directly diminished by the use of 
thiazolidinediones in a dose-dependent manner [12]; thiazolidinediones also decreases 
triglyceride production and circulating free fatty acids by activating PPAR-γ [13].  Therefore, 
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how their distinct structure determines specific functions of each isoform and their locations 
and activities is still not clear [14].  Due to the diversity of tissue distribution and subcellular 
localization, we assume that each ACSL isoform plays a unique role in lipid metabolism.  In 
our study, by using the ACSL4 
L-/- 
mouse model, we aimed to investigate the role of ACSL4 
in hepatic lipid metabolism. 
 
1.3 ACSL4 gene structure and expression 
Long-chain acyl-CoA synthetase 4 (ACSL4) is a member of the ACS family that is 
encoded by the ACSL4 gene found on the X-chromosome [15].  The ACSL4 protein contains 
711 amino acids and exists in brain and steroidogenic tissues [15].  Two identified protein 
domains, AMP-dependent synthetase/ligase and a conserved site with AMP-binding, form 
the enzyme structure [16-19].  On the ACSL4, various sites located on ACSL4 promoter are 
available for different regulatory transcription factors such as Egr-3 [20], SRF [21], AP-2 
gamma [22].  These transcriptional regulators participate in the regulation of ACSL4 genes 
expression in different situations such as embryo development [21], circadian rhythm [20], 
and muscle development [22].  Different splice variants of the ACSL4 gene can produce two 
possible ACSL4 isoforms.  Variant 1 is the truncated isoform of 75KDa molecular weight 
and predicted by PSORT to localize within the cytoplasm [23, 24].  On the other hand, the 
longer variant 2 isoform contains an additional 41-amino acids at the N-terminus [15, 23] 
with a total molecular weight of ~79KDa [15].  The additional 41-amino acids in variant 2 
are highly hydrophobic , targeting this variant to the membranes [24] both the outer nuclear 
membrane and endoplasmic reticulum (ER) membrane [24] of the brain [24, 25]. 
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1.4 ACSL4 location and substrate preference 
Each ACS isoform is likely to have specific fatty acid (FA) preference and can have 
differing tissue distributions.   Compared with other isoforms, ACSL4 has a high affinity for 
polyunsaturated fatty acids (PUFA) including arachidonic acid (AA) (20:4) as substrates [26], 
and it showed lower affinity for mono-, di-, and tri-saturated FAs [26] among the C8–C22 
saturated fatty acids and C14–C22 unsaturated fatty acids that were tested [26].  This result 
was supported by kinetic studies with a purified recombinant Acsl4 from Escherichia coli 
that had been engineered to overproduce rat ACSL4 [26], which has 91% similarity by 
comparison of nucleic acids or a 97% identity for amino acids to human ACSL4 [26, 
27].  The localization of ACSL4 is distinct from other isoforms as well. Specific regions in 
the brain, which includes the cerebellum and the hippocampus, have higher ACSL4 
expression compared to other regions of the brain [26].  The mRNA expression of ACSL4 is 
also detected in steroidogenic tissues including adrenal gland, ovary, and testes [26].  The 
ACSL4 is one of the ACSL isoforms present in human arterial smooth muscle cells (SMCs) 
in addition to ACSL1, ACSL3, and ACSL5 [12]. 
With PUFAs, specifically arachidonic acid the preferred substrate of ACSL4, it is 
likely that ACSL4 plays a significant role in eicosanoid metabolism.  Meanwhile, oxygenated 
AA generates inflammatory products which modulate and mediate the inflammatory 
response.  To prevent excessive synthesis of eicosanoids, which can stimulate inflammation 
and immune reaction, free arachidonate is converted to arachidonoyl-CoA and re-esterified 
into phospholipids as the safe and storage form [28-30].  In general, phospholipid is formed 
by an esterified saturated fatty acid at the sn-1 position of the glycerol backbone, an 
unsaturated fatty acid at the sn-2 position, and a head group linked by a phosphate residue at 
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the sn-3 position.  AA is normally added at the sn-2 position.  Data from rat liver showed 
amongst phospholipid species, 36.3% of PI contains AA [31].  AA is also the most abundant 
unsaturated fatty acid in PE and PC (about 23%) [32].  Upon being absorbed from diet or 
released from phospholipids or other esters by phospholipase A2 (PLA2) [33], AA can be 
further metabolized into different eicosanoids via either the cycloxygenase (COX), 
lipoxygenase (LOX) or cytochrome P450 monooxygenase pathways [34, 35].  The major 
product of the COX pathway is prostaglandins including prostaglandin G2 (PGG2), PGH2, 
and PGE2 [34].  Leukotrienes and hydroxyeicosatetraenoic acids (HETEs) are made by 
activated LOXs and produce their biological effects by interacting with correspondent 
cognate G protein-coupled receptors [34].  Hydroperoxyeicosatetraenoic acids (HPETEs), 
epoxyeicosatrienoic acids (EETs) and HETEs are synthesized from AA by p450 pathway and 
have major effects in the regulation of ion transport [35, 36].  Expression of these 
eicosanoids is tightly controlled by the activity and expression of key enzymes in each 
pathway [35].  Cholesterol ester hydrolase, a key enzyme in steroidogenesis, releases AA 
from cholesterol esters, which is the key regulated enzyme in steroidogenesis [37].  As an 
omega-6 FA with multiple double bonds which are easily oxidized, arachidonic acid exerts 
its influence in multiple ways within vascular cells.  This characteristic is considered a 
contributor of atherosclerotic disease in humans due to its effects on reduction of unstable 
atherosclerotic plaques [38].  Knocking down the Acsl4 in INS 832/13 cells, EETs in the 
media was increased after incubation with 17 mM glucose, and EETs in cell membrane was 
reduced [39].  Glucose-stimulated insulin secretion in those cells was reduced by exogenous 
EETs.  The result indicated in pancreatic beta-cells, ACSL4 catalyzed EET-CoAs activation 
by thioesterify the unesterified EETs. Further, this reaction positively modulates glucose-
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stimulated insulin secretion [39]. However, due to lack knowledge of ACSL4 function in 
liver, whether hepatic EETs will be affect by ACSL4 expression and further alter the hepatic 
lipid metabolism is still unknown.  
 
1.5 Abnormality of ACSL4 in human disease 
A large sequence deletion around the area of the ACSL4 results in a constellation of 
diseases including elliptocytosis, Alport syndrome, and mental retardation (MR) 
[15].  Amongst these diseases, only mental retardation is associated with deficiency of 
ACSL4 [15].  Given that ACSL4 expression is the highest in the hippocampus and the 
cerebellum [26] indicates this enzyme might have an essential role in normal brain 
function.  To investigate ACSL4 function during brain development, investigators showed 
that there was higher expression of ACSL4 in the brain of newborn mouse compared to the 
brains of adult mouse [40].  Alport syndrome, caused by the deletion of the entire COL4A5 
gene which contains ACSL4 encoding sequence, leads to a high risk of renal failure among 
males by adult age [15].  This X-linked illness was potentially caused by an ACSL4 
abnormality that alters neural lipid metabolism [15]. 
 
1.6 Hepatic lipid metabolism and NAFLD with ACSL4 
Non-alcoholic fatty liver disease begins with benign fat accumulation and exacerbates 
by excessive fatty infiltration and inflammation to overt cirrhosis.  Chronically increased fat 
accumulation in the liver impairs the normal hepatic response to insulin, which disturbs the 
production of glucose [41] and VLDL secretion [42, 43].  Insulin resistance impairs the 
regulation of gluconeogenesis in the liver, so that insulin resistance increases hepatic glucose 
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output under an unnecessary condition. Along with impaired glucose uptake in peripheral 
tissues, these abnormal conditions may lead to hyperglycemia [44], hypertriglyceridemia, 
hyperinsulinemia, and a low HDL-cholesterol concentration in circulation [43]. Non-
alcoholic fatty liver disease (NAFLD) is strongly associated with metabolic syndrome such 
as obesity and insulin resistance, and it is identified when the hepatic fat content is above 5% 
of its total weight in the absence of other causes of steatosis [45].  NAFLD includes multiple 
aspects of liver dysfunctions such as simple steatohepatitis (nonalcoholic fatty liver disease 
[NAFL]) and cirrhosis, and can be a precursor to type 2 diabetes, cardiovascular disease, and 
liver failure [46].  In hepatic lipid metabolism, acyl- CoA synthetases are essential in the 
initial step of acyl-CoA formation from free long-chain fatty acids.  ACSL4 has been found 
up-regulated ranged from 2.3 to 27.5 folds in hepatocellular carcinoma compared to non-
cancerous tissues [47].  In in vitro studies within breast cancer cell lines, ACSL4 promotes 
MCF-7 cells proliferation about 1.5- to 2-fold [48, 49].  Meanwhile, in colon cancer the 
overexpression of Acsl4 mRNA has been found ranged between 2.4 to 54.5 fold and ranged 
2.4 to 64 fold of increment of ACSL4 protein expression [50]. Studies using CLOCK-
deficient mice suggest that Acsl4 plays a role in the development of hepatosteatosis as these 
mice had reduced Acsl4 and Fabp1 expression leading to reduced steatosis on a HFD [51].  
CLOCK transcription factor, which is encoded by the clock gene, participates in regulation 
of body temperature and metabolic regulations [51].  This result suggests that Acsl4 
expression or protein function may alter lipid metabolism which is involved in circadian 
control [51].  In human studies, ACSL4 also contributes to the development of human 
hepatocellular carcinoma and adenocarcinoma [47, 52, 53].  Among 302 Finnish subjects 
after adjusting for BMI, sex, and age, researchers first saw polymorphisms in ACSL4 that 
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were significantly related to liver fat content [54].  Higher hepatic lipid content of NAFLD 
patients, accompanied by an increased insulin concentration and obesity, was observed 
among subjects with high expression of a rare allele of ACSL4 rs7887981 [54].  Based upon 
these numerous associations between NAFLD and Acsl4 overexpression, we aimed to 
determine whether ACSL4 expression is the cause or consequence of NAFLD and whether 
ACSL4 deletion would prevent hepatic steatosis in diet-induced obesity.  We hypothesize 
that deletion of ACSL4 will prevent diet-induced non-alcoholic fatty liver disease. 
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Chapter II Development of ACSL4 liver specific knockout mice 
 
ACSL4 deficiency was first indicated in 1% of X-linked mental retardation from 
human studies [15].  Overexpression of ACSL4 has been found in different cancer studies. In 
recent years, ACSL4 was also implicated by the fact that ACSL4 mRNA was 2.8-fold higher 
in the liver of NAFLD patients [54].  However, the function of ACSL4 in lipid metabolism 
and how ACSL4 uniquely impact hepatic lipid homeostasis are not fully understood.  To 
investigate the function of ACSL4, we developed a strain of liver-specific ACSL4 knockout 
mice in C57BJ/6 background by using loxP-Cre strategy. 
 
2.1 Generation of ACSL4 liver-specific knockout mice (Acsl4 
L-/-
) 
The Acsl4 gene is located on X-chromosome Xq22.3-q23 with a total 104,054 base 
pairs and contains at least 17 exons [55].  This gene encodes the ACSL4 protein which has a 
molecular weight of 79kDa.  We have developed an Acsl4
floxed/floxed 
mouse with gene-
targeting vector which is designed to produce a floxed Acsl4 gene. LoxP sites were inserted 
outside exons 3 and 4 of the Acsl4 gene.  Insertion of LoxP sites should not alter the 
expression of ACSL4, but only allow Cre to cut at these sites to remove the DNA between 
the sites.   For positive screening of LoxP insertion, neomycin phosphotransferase (neo) was 
included in the construction of the vector.  A map of the engineered allele with the excision 
of exons 3 and 4 shows the gene structure (Figure 1A).  Stem cells with 129S1/SvlmJ 
background which contained positive gene construction were microinjected into blastocysts 
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with C57BL/6 background to produce transmitting chimeras.  Flpo recombinase expressed in 
transgenic mice was used to excise neo sequence from the targeted allele.  To purify the 
genetic background, heterozygous ACSL4 floxed
 
female mice (ACSL4
+/-
) were back-crossed 
10-times to C57BL/6 mice.  The ACSL4
+/-
female mice were mated with albumin promoter-
Cre transgenic male mice from Jackson lab (JAX Mice Database - 003574 B6.Cg-Tg(Alb-
cre)21Mgn/J), in which the Cre recombinase is uniquely expressed in liver [56].  Because 
Acsl4 is X-linked, we used male knockout mice for our experiments (ACSL4 
L-/-
) and 3 
different groups of littermate controls at first (ACSL4
+/+
-Cre+, ACSL4
+/+
- Cre
-
, and ACSL4
-/-
- Cre
-
) (Figure 1B).  Because the founder Alb-Cre transgenic mice were heterozygous, 
ideally the offspring will have 50% chance to inherit Cre gene.  Using Cre-specific primer, 
we determined the existence of Cre.  The genotype was confirmed with A/B primers which 
were designed to detect LoxP insertion (Table 1A) by using DNA extracted from tail 
samples (Table 1A).  Further ensuring deletion of the Acsl4 in the liver, A/C primers are 
used in PCR solution by using DNA extracted from liver.  Sizes of PCR products by using 
A/B or A/C primers differed from each other (Table 1B).  PCR products from liver samples 
showed knockout genotype with a bright band around 283bp (Figure 1B), whereas that band 
is absent when DNA was extracted from littermate controls (Figure 1B). 
 
2.2   Mating strategies of ACSL4 LoxP-Cre mice 
By crossing an ACSL4
 +/-
 female with a heterozygous Alb-Cre male, we obtained 
ACSL4 
L-/-
 male mice with ideal chance of 12.5%.  To increase the number of ACSL4 
L-/- 
mice produced, we set up new mating cages by developing ACSL4 
floxed/floxed 
females which 
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we interbred with heterozygous Alb-Cre male mice.  The new strategy increased the 
predictedrate of production of male knockout mice to 25% (Table 2). 
 
2.3   Liver Acsl4 mRNA level and protein expression in liver specific knockout mice 
To determine whether deletion of exons 3 and 4 eliminated Acsl4 expression in the 
liver of knockout mice, total RNA was extracted from ACSL4 
L-/- 
livers and littermate control 
livers (Qiagen RNeasy Mini kit).  cDNA was made by reverse transcription (Applied 
Biosystems).  The mRNA level of each ACSL isoform was detected with forward primers 
and reverse primers (Figure 2).  Acsl4 mRNA expression was highly reduced in liver-
specific knockout mice compared with wild-type littermates.  Absence of Acsl4 did not alter 
expression of other ACSL isoforms.  
Mouse peptide antibody against mouse ACSL4 (ACSL4 antibody, supplied by Dr. S. 
Prescott – University of Utah) was used to detect ACSL4 protein expression. We detected a 
~75kDa band in liver from littermates control mice, but ACSL4 protein was absent in liver 
from ACSL4 
L-/-
 mice. ACSL4 protein was still expressed in kidney and gonadal adipose 
tissue from both genotypes, which confirms the liver-specific ACSL4 deletion. (Figure 2B) 
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Chapter III Materials and Methods 
 
3.1 Animal model and tissue collection 
All procedures were reviewed and approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of North Carolina at Chapel Hill (Chapel Hill, NC, 
USA).  Mice from the same generation were housed together in a 12-hour light-dark cycle 
and temperature controlled environment. 
Male mice were weaned around 21 days of age with littermates, and were housed 
together and fed a standard chow diet (Prolab RMH 3000 SP76 chow).  At 8 weeks, ACSL4 
L-/-
 mice and their littermates controls were fed a high fat diet (HFD; 45% calories from fat 
majority from lard), 35% calories from carbohydrate (sucrose and corn starch) Research 
Diets D12451) or an iso-caloric matched diet (10% calories from fat using lard and soybean 
oil, 70% from carbohydrate (matched with sucrose but higher in corn starch) Research Diets 
D12451H) for 20-22 weeks. Weight was recorded weekly.  Oral glucose tolerance tests 
(OGTT) and insulin tolerance tests (ITT) were performed at week 18-19 and week 20-21, 
respectively. One week after the insulin challenge, mice were sacrificed after a 4 h fast (from 
9 am to 1 pm).  Plasma was collected from the retro-orbital sinus and mixed with 10 μl 0.5 M 
EDTA.  Liver, unilateral kidney, unilateral gonadal adipose tissue, and unilateral inguinal 
adipose tissue were weighed, snap-frozen in liquid nitrogen, and stored at -80 °C. 
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3.2 Oral glucose tolerant test (OGTT) and insulin tolerant test (ITT) 
Oral glucose tolerance tests were performed after a 4 hour fast (from 9 am to 1 
pm).  Fasting blood glucose level was measured by glucose monitor (Freestyle) before oral 
gavage (10μl/g) of 20% (w/v) glucose solution (2 g/kg body weight). Blood glucose was 
measured at 15, 30, 60, 90, and 120 minutes after gavage. 
Insulin tolerance tests were performed one week after OGTT. Fasting blood glucose 
level was measured after a 4 hour fast before intraperitoneal injection (i.p.) of 
insulin.  Insulin solution (0.8 IU/kg) was prepared by diluting the insulin stock (100 IU/ml) 
with PBS.  Glucose solution (20% w/v) was available for rescuing if mice experienced 
hypoglycemia when blood glucose lower than 20 mg/dL during the experiment.  Blood 
glucose level was measured at 15, 30, 60, and 90 minutes after intraperitoneal injection (10 
μl/g). 
 
3.3 Liver histology 
Fresh livers were collected from mice after they were anesthetized with 2.5% Avertin 
i.p.  Liver sections were separated from the left lobe and washed with PBS, place in the mold, 
and covered in embedding medium (Tissue-Tek O.C.T compound) which solidifies under -
10 °C. Sections were stored at -80 °C.  Each frozen slide contained sections from two livers 
from both genotypes and was prepared by the Histology Research Core Facility. 
Slides were stained with oil red O (ORO) to visualize lipid droplets.  ORO stock 
solution was made by 400 ml 99% isopropyl alcohol and 2.5 g ORO powder and stored at 
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room temperature.  Diluted ORO stock was diluted 3:2 (v/v) with water to make THE 
working solution and filtered before use. Frozen sections first were air-dried for 10 minutes 
and fixed with 10% formalin solution for 30 minutes.  After rinsing with PBS buffer, slides 
were dipped into ORO working solution for 15 minutes, followed by a wash and then were 
washed with 60% isopropyl alcohol.  A counter stain was done with Mayer’s haematoxylin 
for 1 minute to visualize the nuclei.  Slides were washed with running water for 1 minute and 
mounted in aqueous mounting media (90% glycerol in PBS). 
 
3.4 Liver triglyceride content 
     TAG content was extracted from liver by a modified Folch method [57, 58].  Snap 
frozen liver tissues were homogenized in exactly 10x (v/w) ice cold lysis buffer in a plastic 
microcentrifuge tube. The homogenates were rocked at 4 °C for about one hour, then 100 μL 
liver homogenate of each sample was transferred into tube for TAG content analysis.  
 After addition of methanol: chloroform (1:2, v/v) liver homogenates were vortexed 
and incubated at -20 °C overnight.  0.24 mL 0.88% KCl was added to break the phases and 
the mixture was centrifuged at 4 °C, 1000x g for 15 minutes.  The lower chloroform layer 
was transferred to a new 2mL micro-centrifuge tube and dried under N2.  0.8mL chloroform 
was added to the remaining methanol layer, vortexed, and centrifuged again. The second 
chloroform layer was combined with the previous chloroform extract and dried under N2.the 
dried lipid was resuspended by adding 200μl tert-butanol: methanol: Triton X-100 (3:1:1, 
v/v/v) vortex.   
Glycerol that was hydrolyzed from triglyceride in sample reacts with triglyceride 
reagent. The reaction was visualized by a color change which can be detected at 540 nm after 
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15 minutes incubation at room temperature.  Data was compared to standard glycerol to 
quantify amount of triglyceride per mg of liver tissue (Sigma). 
 
3.5 Acyl-CoA synthetase activity 
     Total ACSL activity in liver homogenates was measured with 2, 4, 6 μg liver 
homogenate at room temperature for 10 minutes with 175 mM Tris (pH7.4), 5 mM 
dithiothreitol, 8 mM MgCl2, 250 μM CoA, 10 mM ATP, 10 μM EDTA, and 50 μM [1-
14
C] 
palmitic acid or 50 μM [14C] arachidonic acid in 500 μM Triton X-100. The total volume was 
200 μl [59]. The reaction was stopped by Dole’s reagent (isopropanol: heptanes: H2SO4; 
v/v/v =80:20:2) and enzymatic activity was calculated by radioactive counts. 
 
3.6 Serum lipid metabolites 
Mice were anesthetized with 2.5% Avertin.  The blood was centrifuged for serum 
collection.  The serum was stored at -80 °C until use. Colorimetirc kits were used to measure 
serum TAG (Stanbio), total cholesterol (Wako), and NEFA (Wako). 
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Chapter IV Investigation of alteration of hepatic lipid metabolism in vitro 
 
After formation by ACS isoforms, acyl-CoAs are distributed to downstream pathways 
that are disparate due to potentially unique roles of each ACS isoform in lipid 
metabolism.  Deletion of ACSL1 causes a 50% decrease of ACSL activity in liver 
homogenate [60], pointing to its role as the major ACSL isoform in this tissue.  Meanwhile, 
under lipogenic and oxidative conditions, ACSL1 mRNA is upregulated [59], which indicates 
its potential role in both pathways.  ACSL4 mRNA expression in liver of NAFLD human 
subjects is 2.8-fold higher than in healthy subjects [61] but studies have yet to shed light on 
ACSL4 function in hepatic liver metabolism.  Therefore, developing diet-induced obesity 
with 45% HFD in ACSL4 
L-/- 
mice provides an opportunity to determine its function. 
 
4.1   Results - Specific activity of total ACSL was identical between genotypes 
     The absence of ACSL1 in mouse liver resulted in about 50% decrease of ACSL 
specific activity [60]; therefore, other ACS isoforms must contribute to the remaining the 
activity.  ACSL4 is the only ACSL isoform whose gene expression is altered under NAFLD 
conditions.  We assumed that in our mouse model, by knocking out ACSL4, the total ACSL 
activity would differ from the activity in littermate control liver.  Total ACSL activity was 
measured with liver homogenates from KO and littermate controls fed a HFD.  Arachidonic 
acid, (Figure 7A) considered to be the preferred substrate for ACSL4 [20], and palmitic acid 
(Figure 7B) were used as substrates.  With either fatty acid substrate, total ACSL activity 
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was unchanged in KO liver homogenates compared to control.  This result indicates that the 
deletion of ACSL4 did not alter ACSL specific activity in liver. 
 
4.2   Results - Serum lipid content was unaltered after deletion of ACSL4 in liver 
Long-term high fat feeding in mice mimics the Western diet which is considered as 
the culprit of pandemic obesity and type-2 diabetes in human.  Risk of NAFLD is increased 
by obesity and exacerbated by insulin resistance (IR).  Under IR state, restriction of lipolysis 
in adipose tissue is removed, resulting in an increase in free fatty acids release into the 
circulation, exacerbating the burden of fatty acid influx into liver [41, 62].  Increased hepatic 
lipid accumulation may also lead to decreased release of FA from VLDL and reduced fatty 
acid oxidation [6].  These changes have a great impact on whole body lipid homeostasis.  A 
lard-based HFD contains large amount of saturated fat and cholesterol esters.  Increased total 
serum cholesterol and body weight was reported when B6 mice were fed a 40% HFD, but 
total triglyceride and blood glucose were unaltered compared to a 17% LFD [63].  To 
examine if liver-specific ACSL4 deletion in our mouse model would disturb plasma lipid 
homeostasis, we measured common lipid metabolites in plasma.  Total cholesterol, 
triglyceride, and NEFA values were determined in serum samples from ACSL4 
L-/-
 mice and 
littermate controls fed a 45% HFD for 20 weeks (Table 3).  No differences were observed 
for serum concentrations of total cholesterol, triglyceride, and NEFA between the two 
genotypes after 20 weeks of 45% HFD-feeding.  Compared to LFD controls, HFD 
significantly increased serum NEFA and cholesterol, but serum triglyceride was decreased 
after HFD feeding.   
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Chapter V Physiological siginificance of ACSL4 
L-/-
 mice fed a 45% fat diet 
 
Rodents, one of the major mammalian laboratory models, are widely used for human 
disease investigation because of their metabolic similarity to humans.  To mimic human 
obesity in murine models, the development of obesity is usually induced by either a genetic 
mutation or a diet challenge.  Ob/ob mice, a widely used genetic mutation model for human 
obesity, develop dramatic weight gain and metabolic disturbance due to the lack of leptin 
secretion.  However, obesity in humans is, in its majority, due to a chronic progression. Apart 
from a genetic abnormality, consuming high-density caloric food and living a sedentary life 
act as the major contributing factors to the pandemic proportions of obesity.  Therefore, 
aiming to imitate this gradual onset of obesity, we fed C57BL/6 mice with a 45% HFD.   The 
C57BL/6 mouse is the most popular inbred strain for laboratory use and is normally used as 
the background strain modeling various human diseases.  Compared to other strains, 
C57BL/6 mice easily develop diet-induced obesity and type 2 diabetes [64].  This 
susceptibility allows us to investigate the effects of NAFLD derived from diet-induced 
obesity on transgenic mice challenged by 45% HFD for 20 weeks. 
 
5.1   Results - Diet-induced obesity developed after HFD-feeding. 
To explore whether the absence of ACSL4 in liver would disrupt whole body 
metabolic homeostasis, ACSL4 
L-/-
 male mice and littermate controls were fed a 45% HFD or 
a 10% LFD matched with sucrose.  We were aiming to investigate a diet-induced onset of 
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NAFLD by using this mouse model to establish a diet-induced obesity.  It is reported that 
body weight gain is not impacted by age of diet initiation (3, 6, or 9 weeks of age) [65].  In 
another study with 45% HFD feeding, C57BL/6 mice displayed insulin resistance at week 12 
[66]. After 21 weeks, these mice showed significant weight gain compared to LFD, along 
with increased adipose tissue mass and hepatic fat storage [66].   Therefore, in our study mice 
were weaned after 21 days and housed together.  We started the diet for 20 weeks when the 
mice were 8 weeks old.  To minimize error from circadian rhythm, body weights were 
recorded each week on Fridays at 9 am.  By the end of 20 weeks, the weight difference was 
not significant between genotypes fed a LFD (Figure 3A) (p=0.26).  However, under HFD, 
the average weight of ACSL4 
L-/-
 was 3 gram lower than that of their littermate controls.  
Significant weight difference developed after 20 weeks between HFD and LFD regardless of 
their genotypes, which indicated a diet-induced obesity.  The weight difference between diets 
developed at week 5 (p<0.05) for control mice but this diet-induced weight difference was 
delayed until week 19 for their knockout littermates (p<0.05).  Analysis of net weight gain 
during the diet period showed that mice of both genotypes fed the HFD gained more weight 
when compared to mice fed the LFD (p<0.05) (Figure 3B).   Together these data indicate 
that after HFD feeding, mice developed diet-induced obesity regardless of genotypes, and the 
deletion of ACSL4 in liver decreased the total body mass by 3 g compared to littermate 
controls. 
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5.2   Results - Oral glucose tolerance and insulin tolerance tests were similar between 
genotypes 
Obesity induces insulin resistance in both human and animal models. Impaired insulin 
response decreases glucose uptake from peripheral tissues such as adipose tissue and 
muscle.   In liver, insulin resistance also accounts for increased gluconeogenesis which 
further affects lipid metabolism.  In wild-type mice, obesity, altered glucose metabolism, and 
insulin resistance occur after a 45% HFD [63].  To test whether the insulin response differed 
in WT and ACSL4 
L-/- 
mice, an OGTT was performed after mice were fed a HFD for 18 
weeks.  In our study, within the HFD group, the glucose peak at 15 minutes after gavage was 
slightly higher in ACSL4 
L-/-
 mice compared to littermate controls, but the difference was not 
significant (Figure 4A).  Calculation of the area under the curve (AUC) above the baseline 
glucose showed that among HFD-fed mice, the AUC of ACSL4 
L-/-
 mice was higher 
compared to their littermate controls but not statistically different (p=0.28) (Figure 
4B).  Mice fed a 10% LFD showed a similar response to glucose treatment for both 
genotypes; however, by comparing diets, mice fed the HFD were glucose intolerant (p*<0.05) 
compared to mice fed the LFD. 
The ITT was performed one week after the OGTT. No significant differences were 
found between genotypes fed each diet (Figure 5A, B); however, with the same dose of 
insulin, mice fed the LFD experienced a higher rate of hypoglycemia.  More than half of 
mice fed LFD needed to be rescued with a 20% glucose injection, whereas hypoglycemia did 
not occur in HFD-fed mice.  Mice fed the LFD were significantly more sensitive to insulin 
treatment compared to mice fed the HFD. (p*<0.05) To summarize, mice fed 45% HFD 
developed diet-induced insulin resistance (IR) after 20 weeks, but the status of IR was not 
different between genotypes.  
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5.3   Results - Liver histology by oil red O staining showed inconsistent differences of  
lipid content between genotypes 
A liver triglyceride content of more than 10% of total liver weight, which cannot be 
accounted for by excessive alcohol intake or viral infection, is identified as NAFLD [67].  To 
detect NAFLD development in our mouse model, we used ORO staining, a technique 
commonly used for visualizing intracellular neutral lipids including triglycerides and 
cholesterol esters.  Liver frozen sections were prepared without fixation, to avoid 
compromising the staining process.  To solve this problem, we optimized a post-frozen fixing 
protocol by using 10% formalin to fix tissue for 30 minutes, as described in the methods 
section.  By ORO staining, the number of lipid droplets in liver from mice fed a 45% HFD 
was vastly higher compared to mice fed a 10% LFD.  Though different sizes of lipid droplets 
were observed between genotypes in the HFD-fed group, the results were not consistent in 
paired samples and no significant difference was found between genotypes (Figure 6).  
 
5.4   Results - Liver triglyceride content 
To quantify hepatic lipid content in the presence or absence of ACSL4 expression, we 
measured TAG mass in homogenized snap-frozen liver samples from 45% HFD fed animals 
after a 4 hour fast.  With 7 mice for each genotype, triglyceride mass (normalized to tissue 
mass) was not significantly different between genotypes.  (Figure 8 and Table 3) These data 
indicate that the deletion of ACSL4 in liver had no impact on triglyceride accumulation 
compared to littermate controls.  This finding was consistent with our liver histology results. 
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Discussion 
 
NAFLD  was first described in 1979 by Adler and Schaffner  that the disease is 
characterized as striking fat accumulation and increased hepatic inflammation within the liver, 
and it potentially leads to cirrhosis [68].  NAFLD mimics the pathogenesis of alcoholic liver 
disease, but it is not due to either alcohol toxicity or virus infection [68]. The term NAFLD 
was widely used after 1980 when Ludwig further confirmed the disease characteristics 
among patients with an abnormal liver function test [69].  In 2013 there were 28.8 million of 
American adults who suffered from NAFLD [70] and it has become a worldwide pandemic.  
Many studies have tried to elucidate the mechanism(s) involved in disease initiation and 
exacerbation.  However, the mechanism(s) remain unclear. 
NAFLD frequently occurs while obesity, type-2 diabetes, and hyperlipidemia are 
developing [71].  In fact, most NAFLD patients were moderately obese and share the many 
characteristics of metabolic syndrome [72].   However, these conditions also occur 
independently.   In non-diabetic patients, the liver fat accumulation is also associated with 
total body mass index which is exacerbated in severe obesity [73].  Even though obesity is a 
major risk factor for NAFLD, non-obese individuals are also at risk of developing NAFLD 
[74-76].  
To investigate complicated disease development, we need to incorporate 
interdisciplinary studies which help to dissect the question from pandemic trend in a
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population to a particular mechanisms in individuals.  Based upon the fact that ACSL4 is the 
only ACSL isoform which is over-expressed in the liver of NAFLD patients [48], we 
hypothesized that ACSL4, as one of the ACSL isoforms that activate—free fatty acids—for 
disparate lipid metabolic pathways, would be required for the development of human 
NAFLD.  However, no research has been reported to illustrate the ACSL4 function in liver 
disease.  Human ACSL4 and rodent ACSL4 are highly similar [15].  This enzyme similarity 
provides the ability to study the function of ACSL4 in a rodent model in order to mimic the 
human response.  Thereupon, we hypothesized that deleting ACSL4 in the liver may prevent 
the transgenic mice from developing diet-induced NAFLD.   
Our previous unpublished study with ACSL4
 L-/- 
mice fed with a 45% HFD showed 
liver lipid content had a 50% decrease compared to wild-type controls; however, the low 
breeding rate of our initial mating strategy resulted in a limited number of mice therefore we 
only compared two ACSL4 
L-/-
 mice with one C57B6 wild-type control.  An improved mating 
strategy increased breeding rate about 2-fold, and KO mice were all matched with floxed 
littermate controls.  The LoxP-Cre strategy was used to generate ACSL4 liver-specific 
knockoutby deleting exons three and four.  Quantitative real time PCR showed that Acsl4 
mRNA expression was more than 94% knocked down in the ACSL4
 L-/- 
liver.  The 
diminished Acsl4 expression did not trigger the compensatory effect on other Acsl isoforms.  
Compared to littermate controls, the protein expression of ACSL4 was completely eliminated 
in liver.  Interestingly, total ACSL activity in liver was unchanged by the absence of ACSL4 
compared to littermate controls using either arachidonic acid or palmitic acid as substrates.  
After a high fat diet challenge, both ACSL4 
L-/-
 and littermate control mice had significant 
weight gain after 20 weeks compared to a sucrose-matched 10% LFD.  Significant weight 
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loss was observed in ACSL4 
L-/-
 compared to littermate controls (Figure 3).  Further 
evaluations on liver lipid content showed large variations (Figure 8) between different 
individual mice but the average lipid content was similar between genotypes.  Fatty liver 
developed in mice fed a HFD but not LFD.  This result conflicted with our preliminary 
observation which may have been due to the limited sample size and incorrect comparisons.  
Serum TAG, cholesterol, and NEFA were unchanged between genotypes.  Serum NEFA and 
total cholesterol level was significantly increased after feeding a HFD due to the large 
amount of saturated fat in the diet.  The decreased fasting serum TAG after HFD feeding 
resulted in the suppression of de novo lipogenesis in liver.  While mice fed the isocaloric 
LFD which contains a high amount of carbohydrates, they had an increase in de novo 
lipogenesis to compensate for the loss of fat.  These data are consistent with a previous study 
which showed the increased carbohydrate content in the LFD induces de novo lipid synthesis 
and VLDL secretion in liver [77]. Overall, the absence of liver ACSL4 did not induce any 
alteration on the ability of reproduction, glucose/insulin responses, total ACSL activity in 
liver, or hepatic lipid metabolism. Only total body weight difference has been observed in the 
liver-specific ACSL4 knockout, but the effect is unrelated to liver lipid metabolism and 
NAFLD development. 
Identical to other ACSL isoforms, ACSL4 also can facilitate FA activation by forming 
acyl-CoAs.  However, chromosomal location, tissue distribution, subcellular location, 
enzyme activity and FA preferences for each ACSL isoform differ from one another.  It is 
further implied that apart from FA activation, each isoform may affect the fate of lipid 
products in different metabolic pathways.  Acsl4, also called Facl4, was first discovered in 
the rat in 1997 [26] and the gene was located on the X-chromosome [15].  The global 
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knockdown of ACSL4 in mice causes embryonic lethality of ACSL4 KO male offspring, 
decreases fertility and causes small litters of heterozygous female offspring when mated with 
C57B6/J male mice [50].  The data indicated ACSL4 is essential for fetal development, 
especially in male offspring due to the X-linked characteristic.  In the ACSL4 liver-specific 
knockout mouse model, we did not observe any phenotype differences of pregnancy in 
female. To exclude sex bias and due to the higher possibility of having ACSL4 
L-/- 
in male, 
we used ACSL4 
L-/-
 male mice to detect liver-specific ACSL4 knockout phenotype 
differences.   Significant decrease in total body weight was found in ACSL4 
L-/-
 male mice 
after 20 weeks HFD challenge, compared to littermate controls (Figure 3).  This result 
indicated merely removing ACSL4 from liver may reduce growth rate and weight gain, but 
the mechanism of how ACSL4 changes total body weight needs to be further investigated.  
ACSL4 has a distinct tissue distribution [26].  In humans, ACSL4 RNA is widely 
distributed in brain, heart muscle, and skeleton muscle, and reproductive organs, but it was 
not detected in liver [15].  A small amount of protein expression is found in human 
hepatocytes, whereas there is a larger amount of expression found in the cerebellum, adrenal, 
or testis (www.proteinatlas.org).  In our mouse model, western blot showed the similar 
existence of abundant ACSL4 in cerebellum and adrenal glands of both KO and control mice 
(Figure 2B); however, ACSL4 in testis of both genotypes was difficult to detect (data not 
shown).  This fact raises the question of whether ACSL4 would be up-regulated in mice after 
NAFLD development.  ACSL4 function in human and rodents may vary after the onset of 
liver disease onset.   
Due to differential splicing, ACSL4 expression produces two variants, a brain-specific 
isoform variant 2 [24, 25] and a ubiquitous variant 1 [9].  Variant 1 has been found to 
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associate with the inner plasma membrane as well as in the cytosol[9].  In our project, total 
ACS activity was measured by using liver homogenates from ACSL4 
L-/-
 and littermate 
controls.  The removal of ACSL4 in liver did not influence enzyme specific activity when 
using either palmitic acid or arachidonic acid, the preferred fatty acid for ACSL4 [26].  It 
might because ACSL4, as a minor amount of ACSL isoform in liver, did not contribute to the 
activation of fatty acids.  In fact, in the ACSL1 liver-specific KO model, the ACSL specific 
activity was 50% lower compared to control which indicated the ACSL1 is an abundant 
hepatic ACSL isoform [60].  Therefore, in ACSL4 
L-/- 
liver, total ACSL activity is unaffected 
by the removal of ACSL4.   
The liver, serves as the central lipid factory, and governs various lipid species 
production and transportation throughout the body.  This process not only refers to the intake 
of lipoprotein particles from circulation, but also includes lipid assembly and output, and 
energy maintenance for liver itself.  Meanwhile, this whole system is modulated under 
different health conditions and diet challenges.  Dietary lipids and FAs released from adipose 
tissues comprise the lipid influx to liver.  Within liver, de novo lipogenesis is stimulated by 
insulin signaling and is increased by energy surplus.  Furthermore, abundant energy promotes 
triglyceride synthesis which can be either stored or released from liver into blood circulation 
as VLDL. Under energy depletion, fatty acids from either the local lipid pool or the free fatty 
acid derived from adipose tissue lipolysis are degraded through oxidation for energy 
production.   Under insulin resistant state, which was also established in our mouse model 
(Figure 4, 5), enhanced circulating FAs influx and hyperinsulinemia stimulates hepatic lipid 
synthesis and blunts hepaticβ-oxidation.  By assuming that lack of ACSL4 was protective 
against NAFLD, we expected to see a phenotype difference on hepatic lipid accumulation 
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because it is the main feature of NAFLD [45].  However, after 20 weeks 45% HFD, no 
difference in hepatic lipid content was found between ACSL4 
L-/-
 and littermate controls 
(Figure 8, Table 3), and triglyceride levels largely differed from each individuals.  Therefore, 
we conclude that activated FFA by ACSL4 in liver may not be required for lipid 
accumulation.  Alternatively, ACSL4-derived products may be used in signaling molecules 
formation and affect the growth process of other tissues such as skeleton muscle which 
would require further investigation. 
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Conclusion and further investigations 
 
Taken together, in liver-specific ACSL4 knockout mice, the absence of ACSL4 did 
not have major effects on hepatic lipid accumulation.  No phenotypic difference was 
observed when mice were fed a high fat diet which induces impaired insulin response and 
glucose intolerance, and enhanced serum lipid content in both genotypes.  I concluded that 
the ACSL4 deletion does not prevent the onset of NAFLD in mice.   
Compared to hepatic ACSL4 function, neurological development and carcinogenesis 
research reported that ACSL4 is highly related to those diseases pathogenesis.  Drosophila, 
as a model for neurological science, was widely used to investigate ACSL4 neuronal 
functions [78].  Drosophila dAcsl is an ortholog of human ACSL3 and ACSL4 [78].  It was 
also identified to localize on ER [78] which is the same localization as human ACSL4 variant 
2 [23, 24].  During the formation of glia and neurons, lack of ACSL4 resulted in reduction of 
decapentaplegic (Dpp), one of the Drosophila vertebrate bone morphogenetic proteins (BMP) 
homologs [78].  Dpp signaling was reported to initiate neuronal differentiation and 
proliferation [79].  ACSL4 mutation blunts the Dpp signaling pathway and further impedes 
neuron development which may mimic a pathogenic process in human X-link mental 
retardation [78].  Synaptic growth, however, was inhibited by ACSL4 homolog dAcsl by 
attenuating BMP signaling [80].  Therefore, even within brain, ACSL4 has specific function 
in different regions.  Even though ACSL4 function in brain has not been fully understood, 
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mounting research suggests that ACSL4-derived lipid products may have important effects 
on neuron growth and signaling transmission [81].  A potential assumption of neuronal 
ACSL4 function is membrane formation which may involve ACSL4-derived phospholipids 
which contain arachidonic acid [82].  Lack of ACSL4 impairs neuronal differentiation and an 
increased content of prostaglandin accumulate in neurons [82]. 
Other than neuronal development, overexpressed ACSL4 was detected in multiple 
cancer cell lines, including specific type of human breast cancer[48], colon cancer [52], and 
liver cancer [47]. It has been found to positively regulate cancer cell growth.  Intracellular 
free arachidonic acid level is reduced by overexpressing ACSL4 and COX-2 in colon cancer 
and apoptosis is prevented by the excessive enzyme expression [52].  On the contrary, 
increasing the intracellular AA level by using triacin C to inhibit ACSL activity or by adding 
exogenous AA, induced apoptosis [52].  In hepatoma cells, increased ACSL4 expression has 
been found, and the inhibition of ACSL4 expression directly decreased cancer cell growth 
[47].  In this study, by adding one type of cyclic AMP (cAMP) analog – one of the second 
messengers in intracellular signaling pathway – ACSL4 expression is suppressed in the 
hepatoma cells [47].  To investigate downstream pathway of cAMP and ACSL4 interaction, 
the study found that p38 phosphorylation was up-regulated in tumors cells but its activity can 
be restricted by cAMP [47].   p38 can be stimulated by growth factors, cytokines, and it 
transmits intracellular signaling to nuclei by modulating gene expression [83].  By using p38 
inhibitor, the study found the ACSL4 expression was blocked [47].  This result suggested that 
p38 was involved in the interaction of cAMP and ACSL4 expression in hepatoma cells [47].  
There are several limitations of my current project which can be improved in future 
investigation.  First, we need biomarkers to identify the development of NAFLD.  Even 
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though increasing hepatic lipid content is the major marker of fatty liver, in our study not all 
mice fed with a 45% HFD established a dramatic increase of liver triglyceride which 
happened in both KO and littermate controls.  During the progression of NAFLD, liver cells 
rupture and release hepatic ALT and AST into the blood stream.  Hepatic ALT and AST can 
be detected in serum to determine disease onset.  Second, significant weight loss was 
observed in ACSL4 
L-/-
 male mice (n=10) fed a 45% HFD for 20 weeks.  The current research 
indicated ACSL4 liver-deletion did not alter liver lipid metabolism; however, the liver-
specific genetic change may affect nutritional metabolism in other tissues by releasing 
signaling molecules. Furthermore, the weight difference may also relate to food intake, basal 
metabolic rate and physical activity, and different lean/fat mass proportion. Third, different 
proportion of phospholipid FA species may result from the lack of ACSL4.  A recent study 
indicated that increased phosphatidylinositol was observed along with ACSL4 
overexpression which supports my conclusions [9].  I assume that removal of ACSL4 in liver 
will alter phospholipid metabolism even if ACSL1 is supposed to be the predominant ACSL 
isoform in mouse liver, because an overexpressing ACSL4 was observed to alter 
phospholipid formation rather than ACSL1 [9].   Fourth, in my current project, although no 
evidence elucidated a possible causality between hepatic ACSL4 function and NAFLD 
development, ACSL4 itself could be a biomarker for NAFLD onset. 
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Figure1. Acsl4 flox PCR strategies 
A. By flanking LoxP sites at sides of exon 3 and 4, the targeting gene structure yielded exon 
3 and 4 deletion when crossed to albumin-CRE animals. Deletion of exons 3 and 4 caused 
immediate translational stops from exon 2 to downstream exons which stopped ACSL4 
protein expression.  Neo sequence helps to screen the positive transgene.  After back-crossing 
10 times to C57BL/6 mice, Acsl4 flox gene was stable in C57BL/6 background.  
B. PCR amplification of loxP site and Acsl4 deletion in liver. Heterozygous ACSL4 
+/-
 female 
mice were interbred with Alb-cre heterozygous male mice to produce ACSL4 
L-/-
 mice and 
littermates controls. A 243 bp band indicated loxP was inserted into Acsl4 gene and a 141 bp 
band indicated normal Acsl4 gene.  A 283 bp PCR was produced only in the liver of KO mice. 
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A.                                                                                            B.  
 
Figure2.  Livers from ACSL4 
L-/-
 male mice contain little Acsl4 m RNA compared to other 
ACS isoforms and no ACSL4 expressed compared to littermate controls. 
 
A. mRNA expression in liver from ACSL4 
L-/-
 mice compared to liver from littermate 
controls.  Relative gene expression of Acsl in ACSL4 
L-/-
 mice compared to littermate 
controls (n = 4 for each group).  Total mRNA was isolated from 20 μg liver samples by 
Qiagen RNeasy Mini kit, mRNA was synthesized to LFDNA for SYBR Green quantitative 
PCR. The 5 ACS isoforms gene expression were normalized to the endogenous control, beta-
actin. *p<0.05 versus Acsl4 mRNA expression in littermate controls.  
B. ACSL4 protein level in the liver, cerebellum, and adrenal of ACSL4 
L-/- 
mice and 
littermate controls mice. Homogenates made from liver, cerebellum, and adrenal tissue snap-
frozen sample were subjected to SDS-PAGE by loading 12.5 μg, 25μg, and 12.5μg protein, 
respectively.   After transfer to a polyvinylidene difluoride membrane, membranes were 
incubated with primary anti-ACSL4 peptide polyclonal antibody or anti-GAPDH antibody 
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  A.                                                                                                 B. 
 
Figure3. Weight difference was observed between ACSL4 
L-/-
 male mice and littermate 
controls at the age of 27-week fed with a 45% HFD. No difference was observed between 
genotypes when mice fed a 10% LFD matched for sucrose. 
 
A. Body weight changes in ACSL4 
L-/-
 male mice and littermate controls during 20 weeks fed 
by 45% HFD compared with 10% LFD.   
* P<0.05 ACSL4 
L-/-
 mice and control mice fed by HFD versus LFD (Student’s t-test) 
# 
P<0.05 ACSL4 
L-/-
 mice versus control mice fed a HFD at the end of the diet 
B. Body weight gain at the end of 20 weeks on the appointed diets. 
Data are shown as mean ±S.E.   * P<0.05 versus control mice fed by LFD (Student’s t-test)  
(HFD control n=10, KO n=12; LFD control n=10, KO n=6) 
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A.                                                                                       B. 
 
Figure4. Glucose response after a glucose oral gavage after 4 hours fast was similar of male 
mice of both genotypes fed a 45% HFD or a 10% LFD for 20 weeks 
 
A. Data are shown as mean ±S.E.  *p<0.05 difference between diets but not genotypes  
B. Area under the curve (AUC).  Data are shown as mean ±S.E.   *p<0.05 difference between 
diets but not genotypes (n=5-7 for each group) 
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A.                                                                                B. 
 
Figure5. Insulin tolerance test (ITT) after 4 hours fast on male mice fed by 45% HFD or 10% 
LFD for 20 weeks had no difference between genotypes. 
 
A. Data are shown as mean ±S.E.  *p<0.05 difference between diets but not genotypes  
At the 60 minute time point, 3 control mice and 3 KO mice required rescue by glucose 
injection. Only 3 control mice and 1 KO mouse finished the whole experiment without 
rescuing.  
B. Area above the curve (AAC) of mice fed by 45% HFD.  
(HFD control n=6, KO n=7; LFD control n=3, KO n=1) 
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                              10% LFD                                 45% HFD 
  
Figure6. No difference showed in liver histology with oil red O staining 
 
Visualization of neutral lipids by ORO analysis in liver from ACSL4 
L-/-
 mice and littermate 
controls fed with a 10% LFD or a 45% HFD for 20 weeks.  Magnification is ×10 each 
sample; n = 3 – 4 per group. 
Left two panels: Representative histology from ACSL4 
L-/-
 mice fed a 10% LFD for 20 weeks. 
Lipid droplets were stained with ORO.  Upper panel is liver from littermate control; lower 
panel is from KO mouse. 
Right two panels: ACSL4 
L-/-
 mice fed a 45% HFD for 20 weeks. Lipid droplets were stained 
by ORO.  Upper panel is liver from littermate control; lower panel is from KO mouse. 
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A.                                                                               B.  
 
Figure7. Total ACS activity in HFD liver was unaltered by ACSL4 deletion compared to 
control liver samples (n=5) 
 
A. ACSL activity in liver with [
14
C]-palmitic acid or [
14
C]-arachidonic acid as substrate 
Liver homogenates obtained from littermate controls and ACSL4 
L-/-
 mice were incubated 
with 50uM labeled fatty acid and reaction reagent for 10 minutes at room temperature.  Data 
are shown as mean ±S.E.  
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Figure8.  HFD-fed mice had higher hepatic TAG content compared to LFD-fed but no 
difference was observed between genotypes 
 
Control HFD n=8; KO HFD n=9; control LFD n=3; KO LFD n=3 
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A.  
Primer Name Sequence  
A ACSL4-F1 CAGTCTTTGGCTGTAAATTGACTATGTGC  
B ACSL4-R1 TGTACCAGTTGCTTGGGAGGAGTACA  
C ACSL4-RSeq4 ACTTGCCAACCAGAAACATGCATAC  
D PGKPR-R1 TGCCTTGGGAAAAGCGCCTC  
 
B. 
PCR product sizes (bp) 
Allele A-B A-D A-C 
+ 141 - - 
neo - 243 - 
c 243 - - 
△3-4 - - 283 
 
Table 1. Primer sequences and product sizes 
 
A. Primers were designed to investigate LoxP insertion sites and Acsl4 deletion.   
B. PCR product sizes.  Liver samples PCR yielded a 283 bp band with A/C primers which 
indicate Acsl4 exon 3 and 4 were excised from liver (knockout mice only).  Tail samples PCR 
produced a 243 bp band with A/B primers which means existed loxP sites and a 141 bp band 
with A/B primers without loxP insertion.  
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A. Original mating strategy  
♂\♀  
X
+
 X
-
 
X
+
 X
+
 X
+
 X
+
 X
-
 
Y 
X
+
Y X
-
Y 
B. Developing homozygous ACSL4 floxed/floxed female 
 ♂\♀ 
X
+
 X
-
 
X
-
 X
+
X
-
 X
-
 X
-
 
Y 
X
+
Y X
-
Y 
C. Current mating strategy 
 ♂\♀ 
X
-
 X
-
 
X
+
 X
-
X X
-
X 
Y 
X
-
Y X
-
Y 
 
Table 2 Breeding strategies of ACSL4 
L-/-
 mice 
 
A. Originally, heterozygous Acsl4 
+/floxed
 female mice were interbred with heterozygous Alb-
Cre male mice to produce ACSL4 
L-/-
 mice with a low rate of 12.5%.  
B. To improve our breeding strategy, homozygous Acsl4 
floxed/floxed
 female mice was 
generated by crossed heterozygous Acsl4 
+/floxed 
female mice with ACSL4 
floxed
 male mice.  
C. With homozygous Acsl4
floxed/floxed 
female mice, new breeding strategy provide 25% 
generation of ACSL4 
L-/-
 male mice when mating with heterozygous Alb-Cre male mice. 
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Table3.  Lipid metabolites in serum and liver 
 10% LFD 45% HFD 
Serum control (n=3) KO (n=3) control (n=9) KO (n=8) 
TAG (mg/dL) 56 ± 7.3  51.5 ± 4.7  37 ± 5.3 * 34 ± 2.1 
#
 
NEFA (mEq/L) 0.26 ± 0.02  0.37 ± 0.05 0.54 ± 0.04 * 0.57 ± 0.02 
Total cholesterol (mg/dL) 90 ± 6.7  104 ± 9.6 144 ± 8.6 * 134 ± 9.1
#
 
Liver     
TAG (μg/mg tissue) 6.2 ± 1.3 11.3 ± 3.7 34 ± 8.1 * 28 ± 5.3 # 
 
Table 3 Liver triglyceride and serum lipid metabolites did not altered in ACSL4 
L-/- 
male 
mice and controls after 4 hours fast 
 
Serum collected from mice after 4 hour fast.  Lipid metabolites were measured by enzymatic 
kits.  Data showed the mean ±S.E. 
Liver triglyceride was extracted by a modified Folch method with lysis buffer.  TAG mass in 
quantitative amount of liver tissue was measured enzymatically.  Data are shown as mean 
±S.E.  
* P<0.05 versus control mice fed by LFD (Student’s t-test) #P<0.05 versus KO mice fed by 
LFD 
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